Skip to Content

Clinical Trial Details

Dasatinib in Newly Diagnosed Brain Cancer Patients

A Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Comibined with Standar Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme.

Objective

To see if adding Dasatinib to the standard of care Temodar and radiation therapy will extend the amount of time it takes for the cancer to start growing again.

Inclusion Criteria:
Must have measurable disease.

Exlusion Criteria:
No prior treatment with radiation or chemotherapy

IRB Protocol Number
NCCTG N0877

Clinical Trial Categories

  • Brain Cancer
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000